Jim said,"Did anyone see a test report that said, "< 10 IU/ml" or did you all see either ">30 IU/ml" or "29" ? Because if no one saw "<10 IU/ml" written on their report, I might have an idea on the discrepencies."
Based on what we have heard here, and what my trial coord has seen, all VL summaries have been expressed as HCV RNA PCR Taqman RUO CL, followed by:
- a number, IU/ml for quant values
- the mystery 29
- <30IU/ml, no HCV RNA detected
Have not heard of anyone in the trail who has a <xxIU/ml value other than 30.
FWIW, my trial coord is following up on this when she is up at Vertex in a week for Prove 3 briefings.
I agree that Vertex is not riba from all that I've seen...in just the small sample groups, what 8 or 9 out of 10 clear very quickly with Vertex? Riba does not have those numbers...as for the rest, I agree that more shall be revealed...
"Have not heard of anyone in the trail who has a ..."
which should have read, "Have not heard of anyone in the trial who has a single result expressed as <10IU/ml."
I'm doing very well, thanks! I'm taking shot 19 today and will have my week-20 visit in a couple of weeks. I'm fortunate that I haven't had the awful side effects endured by you and mremeet (and many others). I'm glad to hear that your doc believes the 29 was a false positive.
I guess I was just pointing out the grey areas that exist in the screening criteria that can give some wiggle room - to the benefit or detriment of the patient trying to get in. In my case, the pathologist's reading declared that I had "evolving cirrhosis" which automatically excluded me from the study. However, in the opinion of the Dr. that was an "overcall" - who read it more as a stage 2 than 3, w/ fibrosis. I felt that the doctor and study nurse worked on my behalf to help me get into the study. On the other hand, I read on another forum that a person was excluded because he said he had a beer in the last 12 months. It seems there's more to selecting a trial participant than labwork.
That is wonderful news. Best wishes to you!
Hi, I hope you're sailing right along, you're at week 12 or 13 now? Anyway, I don't think we'll ever know exactly what all those "cherry picking" criteria are but I don't quite think that they deliberately pick "the best patients posible to achieve success". If that were the case, they may have excluded patients such as myself with a notoriously high vl or APK with a vl of 28M. Mine was 27M a month before start of treatment but had gone down to 15M on the first day of dosing. Why would they have included PLN or APK, both with F-3 livers. Granted, they did exclude anyone whose liver was beyond F3, to my knowledge. So, I'll agree with you that there's bound to be some "cherry picking" but it can't be far and wide or they wouldn't be able to get away with that. THese trials are under close scrunity and they do have to enroll a wide range of subjects with varying degrees of fibrosis, vl, combination genotypes, etc.
Willows may be right about them using even more strict criteria for picking non-responders and that the non-responder group may be smaller than we'd like. I don't know the answer to that but would love to ask my doctor when I see him in the next week or so.